Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

NNASDAQ:CGEM
9.50
USD
-0.78
(-7.59%)
-3.32EPS
996.23MMarket Cap
Mar 17Next Earn
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
(Nasdaq Stock Market)

Recent

price

9.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
0.44
- -
- -
- -
- -
- -
Revenue per Share
-1.24
-1.07
-1.25
-1.52
2.46
-3.69
-3.11
-3.73
-3.32
Basic EPS, GAAP
-1.21
-1.08
-0.72
-1.01
-2.83
-3.24
-2.7
-2.98
-2.7
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.55
-0.98
4.81
9.59
11.68
10.58
10.09
6.78
4.33
Book Value per Share
-0.55
-0.98
4.81
9.59
11.68
10.58
10.09
6.78
4.33
Tangible Book Value per Share
11
19
41
43
45
42
54
59
61
Basic Weighted Avg Shares
- -
- -
- -
19
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-358.73
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-14
-21
-52
-66
111
-153
-167
-220
-203
Net Income, GAAP
- -
- -
- -
- -
27.84
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-346.14
- -
- -
- -
- -
- -
Profit Margin (%)
33
98
198
285
452
452
384
349
258
Working Capital
- -
- -
- -
- -
4
2
1
2
1
LT Debt
-21
-40
200
425
535
454
590
409
281
Total Equity
- -
- -
- -
- -
21.53
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
23.45
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-21.02
23.17
-30.98
-32.06
-44.02
-55.54
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
64
65
Market Capitalization
873
1,172
996

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
361
342
298
Cash, Cash Equivalents & STI
352
335
290
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
35
41
40
Payables & Accruals
30
33
31
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.45%
-30.76%
Free Cash Flow
- -
54.87%
20.99%
Net Income, GAAP
- -
-88.02%
31.36%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.86
-0.76
-0.7
-0.81
-3.11
2025
-0.82
-1.19
-0.86
-0.86
-3.73
2026
-0.82
-0.87
-0.77
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing modality-agnostic targeted therapies for autoimmune diseases and cancer. The company’s product portfolio includes clinical-stage molecules such as CLN-619, CLN-978, zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617, which are designed to inhibit key drivers of disease or leverage the immune system to eliminate diseased cells. Zipalertinib, developed in collaboration with Taiho Oncology, Inc., targets genetically defined subsets of non-small cell lung cancer; CLN-049 is a novel FLT3xCD3 bispecific T cell engager for relapsed/refractory acute myeloid leukemia and recently received FDA Fast Track designation. Cullinan therapeutics also pursues CLN-978 specifically for autoimmune diseases, with systemic lupus erythematosus as a primary indication, reflecting a strategic expansion from oncology into immunology. The company operates primarily in the United States and through partnerships internationally, including Taiho Pharmaceutical in Greater China for commercialization outside the U.S. and China. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cullinan recently changed its name from Cullinan Oncology to reflect its broadened autoimmune disease focus. Recent major developments include the initiation of a rolling submission for zipalertinib’s New Drug Application to the U.S. FDA, discontinuation of enrollment in its B-NHL study to focus on autoimmune diseases, a strategic partnership with Taiho Pharmaceutical for global commercialization rights of CLN-081/TAS6417, and financial positioning with cash resources supporting operations into 2029. The company emphasizes advancing first- or best-in-class therapies through clinical trials for high unmet medical needs in both autoimmune and oncologic therapeutic areas.

Company News

  • New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

  • Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

  • Cullinan Therapeutics to Participate in Upcoming Investor Conferences

  • Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

  • Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

  • Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

  • 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

  • Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA

  • Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

  • Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

  • New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

  • Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

  • Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

  • Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

  • Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

  • Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM

  • Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript

  • Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

  • Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

  • Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer